A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

• ClinicalTrials.gov Identifier: NCT05385783
• Recruitment Status: Completed
• First Posted: May 23, 2022
• Last Update Posted: March 25, 2024
• Sponsor: Cybin IRL Limited
• Collaborators: Clinilabs Drug Development Corporation; Drug Safety Navigator
• Information provided by (Responsible Party): Cybin IRL Limited

Study Description

Brief Summary:

The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).

Condition or disease	Intervention/treatment	Phase
Major Depressive Disorder	Drug: CYB003; Behavioral: Psychotherapy; Drug: Placebo; Behavioral: Psychological Support	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 57 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Relative Bioavailability and Food Effect Cohort to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of CYB003 in Healthy Participants With and Without Major Depressive Disorder (MDD)
• Actual Study Start Date: August 2, 2022
• Actual Primary Completion Date: October 16, 2023
• Actual Study Completion Date: January 18, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: A: MDD Participants - CYB003 in 2 of 2 Medicine Sessions; Arm A MDD participants will receive CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study.	Drug: CYB003; CYB003 is a synthetic psilocybin analog.; Behavioral: Psychotherapy; Manualized psychotherapy (called EMBARK) performed by facilitators
Placebo Comparator: B: MDD Participants - Placebo in Medicine Session 1, CYB003 in Medicine Session 2; Arm B MDD participants will receive placebo in Medicine Session 1, and approximately three weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study.	Drug: CYB003; CYB003 is a synthetic psilocybin analog.; Behavioral: Psychotherapy; Manualized psychotherapy (called EMBARK) performed by facilitators; Drug: Placebo; Placebo
Experimental: C: Healthy Volunteers - CYB003 in 2 of 2 Medicine Sessions; Arm C healthy volunteers will receive CYB003 in 2 of 2 medicine sessions, approximately one to two weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study.	Drug: CYB003; CYB003 is a synthetic psilocybin analog.; Behavioral: Psychological Support; Manualized psychological support performed by facilitators
Placebo Comparator: D: Healthy Volunteers - Placebo in Medicine Session 1, CYB003 in Medicine Session 2; Arm D healthy volunteers will receive placebo in Medicine Session 1, and approximately one to two weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study.	Drug: CYB003; CYB003 is a synthetic psilocybin analog.; Drug: Placebo; Placebo; Behavioral: Psychological Support; Manualized psychological support performed by facilitators
Experimental: E: Healthy Volunteers - CYB003 in 3 of 3 Medicine Sessions; Arm E healthy volunteers will receive CYB003 in 3 of 3 medicine sessions, approximately one week apart from each other, to assess bioavailability and food effect. The CYB003 dose received will depend on the safety review committee selection/time of enrollment. All healthy volunteers will receive psychological support throughout the study.	Drug: CYB003; CYB003 is a synthetic psilocybin analog.; Behavioral: Psychological Support; Manualized psychological support performed by facilitators

Outcome Measures

Primary Outcome Measures :

1. Adverse Events (All Arms) [ Time Frame: Day 1 thru End of Study Visit (which is: Day 56 Arms A & B; Day 28 Arms C & D; Day 35 Arms E) ]
   Any untoward medical occurrence in a clinical investigation participant administered a drug and does not necessarily have a causal relationship with the treatment
2. Resting 12 Lead ECG ventricular rate (Arms A & B) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, & Day 23 ]
   ventricular rate (beats per minute)
3. Resting 12 Lead ECG ventricular rate (Arms C & D) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 ]
   ventricular rate (beats per minute)
4. Resting 12 Lead ECG ventricular rate (Arms E) [ Time Frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 ]
   ventricular rate (beats per minute)
5. Resting 12 Lead ECG PR interval (Arms A & B) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23 ]
   PR interval (milliseconds)
6. Resting 12 Lead ECG PR interval (Arms C & D) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 ]
   PR interval (milliseconds)
7. Resting 12 Lead ECG PR interval (Arms E) [ Time Frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 ]
   PR interval (milliseconds)
8. Resting 12 Lead ECG QRS duration (Arms A & B) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23 ]
   QRS duration (milliseconds)
9. Resting 12 Lead ECG QRS duration (Arms C & D) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 ]
   QRS duration (milliseconds)
10. Resting 12 Lead ECG QRS duration (Arms E) [ Time Frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 ]
    QRS duration (milliseconds)
11. Resting 12 Lead ECG QT interval (Arms A & B) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23 ]
    QT interval (milliseconds)
12. Resting 12 Lead ECG QT interval (Arms C & D) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 ]
    QT interval (milliseconds)
13. Resting 12 Lead ECG QT interval (Arms E) [ Time Frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 ]
    QT interval (milliseconds)
14. Resting 12 Lead ECG QTcF (Arms A & B) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23 ]
    Corrected QT interval by Fredericia (milliseconds)
15. Resting 12 Lead ECG QTcF (Arms C & D) [ Time Frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9 ]
    Corrected QT interval by Fredericia (milliseconds)
16. Resting 12 Lead ECG QTcF (Arms E) [ Time Frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16 ]
    Corrected QT interval by Fredericia (milliseconds)
17. Holter monitoring (Arms A & B) [ Time Frame: Day -1, Day 1, Day 22 ]
    Record of the electrical activity of the heart (Hz)
18. Holter monitoring (Arms C & D) [ Time Frame: Day -1, Day 1, Day 8 ]
    Record of the electrical activity of the heart (Hz)
19. Holter monitoring (Arm E) [ Time Frame: Day -1, Day 1, Day 8, Day 15 ]
    Record of the electrical activity of the heart (Hz)
20. Columbia Suicide Severity Rating Scale (CSSRS) Lifetime version (All Arms) [ Time Frame: Screening ]
    Evaluation tool that evaluates a lifetime history of suicidal ideation and/or behavior. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).
21. Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms A & B) [ Time Frame: Day -1, Day 2, Day 10, Day 17, Day 21, Day 23, Day 31, Day 38, Day 42, and Day 56 ]
    Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).
22. Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms C & D) [ Time Frame: Day -1, Day 2, Day 7, Day 9, Day 15, Day 21, Day 28 ]
    Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).
23. Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arm E) [ Time Frame: Day -1, Day 2, Day 7, Day 9, Day 14, Day 16, Day 21, Day 28, Day 35 ]
    Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

Secondary Outcome Measures :

1. Mystical Experience Questionnaire (MEQ30) (Arms A & B) [ Time Frame: Day 1 & Day 22 ]
   The revised MEQ30 consists of 30 questions looking back on the entirety of a medicine session, participants are asked to answer each question according to one's feelings, thoughts, and experiences at the time of the session. Each item is rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The minimum score is 0 and the maximum score is 150 with higher scores indicating a greater degree of mystical experience. The MEQ total score is computed by taking the average response to all items.
2. Mystical Experience Questionnaire (MEQ30) (Arms C & D) [ Time Frame: Day 1 & Day 8 ]
   The revised MEQ30 consists of 30 questions looking back on the entirety of a medicine session, participants are asked to answer each question according to one's feelings, thoughts, and experiences at the time of the session. each item rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The minimum score is 0 and the maximum score is 150 with higher scores indicating a greater degree of mystical experience. The MEQ total score is computed by taking the average response to all items.
3. Mystical Experience Questionnaire (MEQ30) (Arms C & D) [ Time Frame: Day 1, Day 8, & Day 15 ]
   The revised MEQ30 consists of 30 questions looking back on the entirety of a medicine session, participants are asked to answer each question according to one's feelings, thoughts, and experiences at the time of the session. each item rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The minimum score is 0 and the maximum score is 150 with higher scores indicating a greater degree of mystical experience. The MEQ total score is computed by taking the average response to all items.
4. 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) (Arms A & B) [ Time Frame: Day 1 & Day 22 ]
   The 5D-ASC consists of a set of 94 items that participants are asked to rate to what extent the statements apply to one's particular experience, compared to normal waking consciousness. This has 11 subscales and higher scores are indicative of good outcomes.
5. 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) (Arms C & D) [ Time Frame: Day 1 & Day 8 ]
   The 5D-ASC consists of a set of 94 items that participants are asked to rate to what extent the statements apply to one's particular experience, compared to normal waking consciousness. This has 11 subscales and higher scores are indicative of good outcomes.
6. 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) (Arm E) [ Time Frame: Day 1, Day 8, & Day 15 ]
   The 5D-ASC consists of a set of 94 items that participants are asked to rate to what extent the statements apply to one's particular experience, compared to normal waking consciousness. This has 11 subscales and higher scores are indicative of good outcomes.
7. Hallucinogen Rating Scale (HRS) (Arms A & B) [ Time Frame: Day 1 & Day 22 ]
   The HRS is a questionnaire with up to 100 items and is designed to assess the subjective effects of hallucinogenic substances. Responses to the majority of questions are on a 5 point intensity scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; and 4=extremely. Some questions have a slightly modified scale, and one question asks to rate the amount of time between when the drug was administered and feeling an effect from: no effect, 0 5 minutes, 5-15 minutes, 15-30 minutes, 30 60 minutes, or more than one hour. The minimum score is zero and maximum score is 400 with higher scores indicating greater hallucinogenic effect.
8. Hallucinogen Rating Scale (HRS) (Arms C & D) [ Time Frame: Day 1 & Day 8 ]
   The HRS is a questionnaire with up to 100 items and is designed to assess the subjective effects of hallucinogenic substances. Responses to the majority of questions are on a 5 point intensity scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; and 4=extremely. Some questions have a slightly modified scale, and one question asks to rate the amount of time between when the drug was administered and feeling an effect from: no effect, 0 5 minutes, 5-15 minutes, 15-30 minutes, 30 60 minutes, or more than one hour. The minimum score is zero and maximum score is 400 with higher scores indicating greater hallucinogenic effect.
9. Hallucinogen Rating Scale (HRS) (Arm E) [ Time Frame: Day 1, Day 8, & Day 15 ]
   The HRS is a questionnaire with up to 100 items and is designed to assess the subjective effects of hallucinogenic substances. Responses to the majority of questions are on a 5 point intensity scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; and 4=extremely. Some questions have a slightly modified scale, and one question asks to rate the amount of time between when the drug was administered and feeling an effect from: no effect, 0 5 minutes, 5-15 minutes, 15-30 minutes, 30 60 minutes, or more than one hour. The minimum score is zero and maximum score is 400 with higher scores indicating greater hallucinogenic effect.
10. Persisting Effects Questionnaire (PEQ) (Arms A & B) [ Time Frame: Day 1 & Day 22 ]
    The PEQ is a 5-item questionnaire that assesses the meaningfulness, spiritual significance, psychological insightfulness, and how psychologically challenging a participant experience was during the medicine session. Scores are assessed on a scale from 0 (not at all) to 5 (extremely). Higher scores (under consideration of reverse-scored items) indicate stronger persisting treatment effects.
11. Persisting Effects Questionnaire (PEQ) (Arms C & D) [ Time Frame: Day 1 & Day 8 ]
    The PEQ is a 5-item questionnaire that assesses the meaningfulness, spiritual significance, psychological insightfulness, and how psychologically challenging a participant experience was during the medicine session. Scores are assessed on a scale from 0 (not at all) to 5 (extremely). Higher scores (under consideration of reverse-scored items) indicate stronger persisting treatment effects.
12. Persisting Effects Questionnaire (PEQ) (Arm E) [ Time Frame: Day 1, Day 8, & Day 15 ]
    The PEQ is a 5-item questionnaire that assesses the meaningfulness, spiritual significance, psychological insightfulness, and how psychologically challenging a participant experience was during the medicine session. Scores are assessed on a scale from 0 (not at all) to 5 (extremely). Higher scores (under consideration of reverse-scored items) indicate stronger persisting treatment effects.
13. VAS Ratings of "Any Drug Effect" (Arms A & B) [ Time Frame: Day 1 & Day 22 ]
    The visual analog scale (VAS) for "Any Drug Effect" consists of a 100mm bipolar line with the far-left side of the line marked "not at all" and the far-right side of the line marked "extremely" to assess if participants feel any drug effect.
14. VAS Ratings of "Any Drug Effect" (Arms C & D) [ Time Frame: Day 1 & Day 8 ]
    The visual analog scale (VAS) for "Any Drug Effect" consists of a 100mm bipolar line with the far-left side of the line marked "not at all" and the far-right side of the line marked "extremely" to assess if participants feel any drug effect.
15. VAS Ratings of "Any Drug Effect" (Arm E) [ Time Frame: Day 1, Day 8, & Day 15 ]
    The visual analog scale (VAS) for "Any Drug Effect" consists of a 100mm bipolar line with the far-left side of the line marked "not at all" and the far-right side of the line marked "extremely" to assess if participants feel any drug effect.
16. Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from screening (Arms A & B) [ Time Frame: Screening, Day -1, Day 1, Day 10, Day 17, Day 31, & Day 38 ]
    The minimum and maximum values are 0 and 60 with a higher score indicating a worse outcome.
17. Pharmacokinetic parameter of psilocin (Cmax) (Arms A & B) [ Time Frame: Day 1, Day 2, Day 22, & Day 23 ]
    Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data.
18. Pharmacokinetic parameter of psilocin (Cmax) (Arms C & D) [ Time Frame: Day 1, Day 2, Day 8, & Day 9 ]
    Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data.
19. Pharmacokinetic parameter of psilocin (Cmax) (Arm E) [ Time Frame: Day 1, Day 2, Day 8, Day 9, Day 15, & Day 16 ]
    Cmax: maximum concentration of plasma psilocin determined from concentrations-versus-time data.
20. Pharmacokinetic parameter of psilocin (AUC) (Arms A & B) [ Time Frame: Day 1, Day 2, Day 22, & Day 23 ]
    AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule.
21. Pharmacokinetic parameter of psilocin (AUC) (Arms C & D) [ Time Frame: Day 1, Day 2, Day 8, & Day 9 ]
    AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule.
22. Pharmacokinetic parameter of psilocin (AUC) (Arm E) [ Time Frame: Day 1, Day 2, Day 8, Day 9, Day 15, & Day 16 ]
    AUC: Area under the plasma concentrations-versus-time curve determined using the linear trapezoidal rule.

Eligibility Criteria

• Ages Eligible for Study: 21 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria - MDD & Healthy Volunteer Participants:

• Aged between 21 to 65 years, inclusive, at Screening.
• Has a BMI of 18 to 30 kg/m2, inclusive, at Screening.
• Is ≥60 kg.
• Is negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test at Screening and at Day -1.
• Provision of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Additional Inclusion Criteria - MDD Participants Only:

• Has a diagnosis of MDD (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition [DSM-V] of moderate to severe degree), established through a full psychiatric work up, who are otherwise healthy.
• Has been on a stable dose of antidepressant medication (no more than 50% change) in the last month prior to Screening and has had an inadequate response, as judged by the Investigator.

Exclusion Criteria - MDD & Healthy Volunteer Participants:

• Clinically significant risk of suicidality, as determined through a comprehensive psychiatric interview.
• Clinically relevant history of abnormal physical health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including [but not limited to], neurological, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder).
• Diagnosis of hypertension or an arrhythmia.
• History of hypothyroidism and/or current abnormal thyroid function tests.
• Clinically relevant abnormal laboratory results.
• History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drug.
• Any other concomitant disease or condition that could interfere with, or for which the treatment might interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study.
• Not fluent in the English language.
• Has a presence or relevant history of any of the following medical conditions: organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions).
• Positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibody (anti- HCV) or human immunodeficiency virus I and II (anti-HIV I/II) at Screening.
• Has participated in a clinical study and has received a medication or a new chemical entity within 3 months prior to dosing of current study medication.
• Is taking or has taken any drugs known to inhibit monoamine oxidase within 28 days prior to receiving the study drug.
• Is taking or has taken over the counter (OTC) doses of 5-hydroxytrptophan or St John's Wort within 28 days prior to receiving the study drug.
• Donation of blood or plasma of >400 mL within 1 month prior to first dosing until 4 weeks after final dosing.
• Is pregnant, breastfeeding or planning to conceive.
• Known difficulty with obtaining intravenous access.
• Other eligibility considerations (i.e., participant personal circumstances, behavior, and/or any current problem that might interfere with participation or that is incompatible with establishment of rapport or safe exposure to the study drug), as judged by the Investigator.

Additional Exclusion Criteria - Healthy Volunteers Only:

• Current or previously diagnosed with a mental health disorder as defined by DSM-V criteria.
• Use of any prescription medicine (except for hormonal contraceptives, if applicable), certain herbal supplements (to be reviewed by the Investigator), or OTC medicine during the 28 days before dosing.

Additional Exclusion Criteria - MDD Participants Only:

• Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments given at an adequate dose for an adequate duration.
• Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder or brief psychotic disorder; current or previous history of bipolar disorder, or current personality disorder.
• Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, mirtazapine, an antipsychotic or a mood stabilizer.
• Use of a prescription medicine (except participants may take a stable chronic dose of antidepressant medication(s) and/or sedatives/hypnotics, and may take hormonal contraceptives, if applicable), certain herbal supplements (to be reviewed by the Investigator), or OTC medicine during the 28 days before dosing (some exceptions apply).

Contacts and Locations

Locations

United States, Georgia

CenExel ACMR

Atlanta, Georgia, United States, 30331

iResearch Atlanta

Decatur, Georgia, United States, 30030

United States, New Jersey

Clinilabs Drug Development Corporation

Eatontown, New Jersey, United States, 07724

Sponsors and Collaborators

Cybin IRL Limited

Clinilabs Drug Development Corporation

Drug Safety Navigator

Investigators

• Study Director: Amir Inamdar, MBBS,DNB,MFPM; Cybin IRL Limited

More Information

Additional Information:

New Jersey Site Recruitment Website. Please click on link to apply 

• Responsible Party: Cybin IRL Limited
• ClinicalTrials.gov Identifier: NCT05385783
• Other Study ID Numbers: CYB003-001
• First Posted: May 23, 2022
• Last Update Posted: March 25, 2024
• Last Verified: March 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Cybin IRL Limited:

Major Depressive Disorder; MDD; Psilocybin; Psychedelic; Psilocin; CYB003; CYB003-001; Depression; Healthy

Additional relevant MeSH terms:

Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders; Behavioral Symptoms